Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Primaquine (compound)


PubChem
Name: Primaquine
PubChem Compound ID: 185162
Description: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
Molecular formula: C15H21N3O
Molecular weight: 261.359 g/mol
Synonyms:
92362-33-9
DrugBank
Identification
Name: Primaquine
Name (isomeric): DB01087
Drug Type: small molecule
Description: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
Brand: Primachin, Neo-Quipenyl
Category: Antimalarials, Antiprotozoal Agents, Antimalarial Agents
CAS number: 90-34-6
Pharmacology
Indication: For the treatment of malaria.
Pharmacology:
Primaquine is an antimalarial agent and is the essential co-drug with chloroquine in treating all cases of malaria. In the blood, malaria parasites break down a part of the red blood cells known as haemoglobin. When this happens haemoglobin is divided into two parts; haem and globin. Haem is toxic to the malaria parasite. To prevent it from being d...
show more »
Mechanism of Action: Primaquine's mechanism of action is not well understood. It may be acting by generating reactive oxygen species or by interfering with the electron transport in the parasite. Also, although its mechanism of action is unclear, primaquine may bind to and alter the properties of protozoal DNA.
Half Life: 3.7-7.4 hours
Affected organisms: Plasmodium
Interactions
Food interaction:
Take with food to decrease dyspepsia.
Drug interaction:
ThiothixeneThe strong CYP1A2 inhibitor, Primaquine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Primaquine is initiated, discontinued or dose changed.
ArtemetherPrimaquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
TacrineThe metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Primaquine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Primaquine is initiated, discontinued or if the dose is changed.
TizanidinePrimaquine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
LumefantrinePrimaquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.

Targets


Enzymes